Advertisement

Topics

Aztreonam for Inhalation Solution (AZLI) vs Tobramycin Inhalation Solution (TOBI®) in Patients With CF & P. Aeruginosa

2014-07-23 21:20:14 | BioPortfolio

Summary

The purpose of this study is to assess the comparative safety and effectiveness of Aztreonam for Inhalation Solution versus Tobramycin Nebuliser Solution in adult and pediatric patients with CF and pulmonary Pseudomonas aeruginosa (PA) infection.

Description

Number of Subjects Planned: Approximately 200 randomized patients

Target Population: CF patients >/= 6 years of age with stable pulmonary disease, who at study entry have a recent positive sputum culture for PA and have been previously treated with aerosolized antibiotics without demonstration of drug intolerance.

U.S Only

Study Design: This is an open-label, multicenter, randomized, parallel group study. The study design consists of two treatment arms of 28-day, intermittent, repeating treatment regimens: Aztreonam for Inhalation Solution (AZLI) or Tobramycin Inhalation Solution (TIS). The total study period will be 26 weeks. The study schedule will include nine visits - Screening, Baseline, Day 14, Day 28, then visits every 28 days through the end of the study.

EU Only

Study Design: This is an open-label, multicenter, randomized, parallel group study. The study design consists of two treatment arms of 28-day, intermittent, repeating treatment regimens: Aztreonam 75 mg Powder and Diluent for Nebulizer Solution (AZLI) or Tobramycin Nebuliser Solution (TNS). The total study period will be 26 weeks. The study schedule will include nine visits - Screening, Baseline, Day 14, Day 28, then visits every 28 days through the end of the study.

An open-label, single-arm extension is available for subjects who have completed at least one course of AZLI or TNS during the randomized portion of the study. Subjects may be eligible to receive three additional cycles of AZLI in a 28-day, intermittent, repeating treatment regimen.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Cystic Fibrosis

Intervention

Aztreonam for Inhalation Solution, Tobramycin Nebuliser Solution

Location

Anchorage
Alaska
United States
99508

Status

Recruiting

Source

Gilead Sciences

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:20:14-0400

Clinical Trials [3119 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

The purpose of this research study is to see if an experimental drug called Aztreonam for Inhalation Solution is safe and effective to treat Burkholderia lung infections in patients with C...

Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis

The purpose of this research study is to determine if multiple doses of two inhaled drugs will help Cystic Fibrosis patients whose lungs are infected with a bacteria called Burkholderia do...

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

This study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler

Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

The aim of this study is to investigate the efficacy of antibiotic therapy with any antibiotic (IV) and IV (Nebcin®) tobramycin for 5 days followed by Solution for nebuliser inhalation (T...

Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis

The purpose of this study is to evaluate tobramycin inhalation solution (TIS) once daily compared tot placebo, and open label twice daily, in patients with non-CF bronchiectasis. The prima...

PubMed Articles [6210 Associated PubMed Articles listed on BioPortfolio]

Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Pseudomonas aeruginosa is a major pathogen of the chronic lung infections in cystic fibrosis (CF) patients. These persistent bacterial infections are characterized by bacterial aggregates with biofilm...

Intermittent inhaled tobramycin and systemic cytokines response in CF patients with Pseudomonas aeruginosa.

CF pulmonary guidelines recommend alternate therapy (one month on, one month off) with inhaled tobramycin for chronic Pseudomonas aeruginosa colonization in cystic fibrosis (CF). Tobramycin-inhaled po...

Early respiratory viral infections in infants with cystic fibrosis.

Viral infections contribute to morbidity in cystic fibrosis (CF), but the impact of respiratory viruses on the development of airway disease is poorly understood.

Authors' response: Letter to the Editor 'Comparison of lung clearance index determined by washout of N2 and SF6 in infants and preschool children with cystic fibrosis'.

Novel Combination Proliposomes Containing Tobramycin and Clarithromycin Effective against Pseudomonas Aeruginosa Biofilms.

s Tobramycin (TOB) and clarithromycin (CLA) can potentially be used synergistically for the treatment of respiratory infections caused by Pseudomonas aeruginosa (P. aeruginosa) in cystic fibrosis (CF)...

Medical and Biotech [MESH] Definitions

Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water).

The pressure required to prevent the passage of solvent through a semipermeable membrane that separates a pure solvent from a solution of the solvent and solute or that separates different concentrations of a solution. It is proportional to the osmolality of the solution.

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)

Solution that is usually 10 percent glucose but may be higher. An isotonic solution of glucose is 5 percent.

More From BioPortfolio on "Aztreonam for Inhalation Solution (AZLI) vs Tobramycin Inhalation Solution (TOBI®) in Patients With CF & P. Aeruginosa"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Trial